Individualized vaccines for cancer

Patent metadata

Field	Value
Publication number	US-2023190898-A1
Application number	US-202217964839-A
Country	US
Kind code	A1
Filing date	Oct 12, 2022
Priority date	Nov 28, 2012
Publication date	Jun 22, 2023
Grant date	—

Abstract

The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.

First claim

1 - 19 . (canceled)

20 . A method comprising:
(a) administering to a cancer subject a first cancer vaccine for inducing a first immune response against one or more shared tumor antigens,
wherein the first cancer vaccine is selected from a set comprising one or more pre-manufactured vaccine products,
wherein each pre-manufactured vaccine product comprises one or more RNA molecules encoding one or more T cell epitopes of one or more distinct shared tumor antigens, and
wherein the pre-manufactured vaccine products in the set are characterized in that at least 80% of subjects having the same cancer type express at least one of the shared tumor antigens in the set of pre-manufactured vaccine products; and
(b) administering to the cancer subject a second cancer vaccine for inducing a second immune response against one or more tumor antigens,
wherein the second immune response is specific for cancer-specific somatic mutations present in cancer cells of the cancer subject,
wherein the second cancer vaccine comprises one or more RNA molecules encoding a plurality of neo-epitopes, and
wherein the plurality of the neo-epitopes comprise a plurality of cancer-specific somatic mutations that are determined to be present in a tumor specimen from the cancer subject.

21 . The method of claim 20 , wherein the second cancer vaccine is produced by a process comprising steps of:
(i) providing a tumor specimen from the cancer subject and a non-tumor specimen; (ii) identifying sequence differences between the genome, exome and/or transcriptome of the tumor specimen and the genome, exome and/or transcriptome of the non-tumor specimen; (iii) designing peptides or a polypeptide comprising epitopes incorporating the sequence differences identified in step (ii); and (iv) producing a vaccine comprising one or more RNA molecules encoding the peptides or polypeptide designed in step (iii).

22 . The method of claim 20 , wherein the cancer-specific somatic mutations are present in the exome of cancer cells of the cancer subject and are non-synonymous mutations.

23 . The method of claim 20 , wherein the cancer-specific somatic mutations are determined using next generation sequencing (NGS).

24 . The method of claim 21 , wherein the step of identifying sequence differences comprises using next generation sequencing (NGS).

25 . The method of claim 21 , wherein the non-tumor specimen is derived from the cancer subject.

26 . The method of claim 21 , wherein the step of identifying sequence differences comprises identifying sequence differences between the exome of the tumor specimen and the exome of the non-tumor specimen.

27 . The method of claim 20 , wherein the second vaccine comprises an RNA molecule encoding a polyepitopic polypeptide that comprises a plurality of the neo-epitopes.

28 . The method of claim 27 , wherein the polyepitopic polypeptide comprises five or more neo-epitopes.

29 . The method of claim 27 , wherein the polyepitopic polypeptide comprises up to 30 neo-epitopes.

30 . The method of claim 27 , wherein a vaccine sequence of each neo-epitope comprises at least five and up to 50 amino acids, and wherein the vaccine sequence comprises (i) the respective cancer-specific somatic mutation(s) and (ii) its epitope flanking regions as present in a respective naturally occurring protein.

31 . The method of claim 30 , wherein the vaccine sequence of each neo-epitope is about 30 amino acids long.

32 . The method of claim 30 , wherein the vaccine sequences of the neo-epitopes in the polyepitopic polypeptide are arranged in a head-to-tail configuration.

33 . The method of claim 30 , wherein the vaccine sequences of the neo-epitopes in the polyepitopic polypeptide are spaced by at least one linker.

34 . The method of claim 33 , wherein the at least one linker comprises 3 to 50 amino acids.

35 . The method of claim 33 , wherein the at least one linker comprises 6 to 50 amino acids.

36 . The method of claim 33 , wherein the at least one linker comprises 6 to 30 amino acids.

37 . The method of claim 33 , wherein the at least one linker comprises (i) glycine amino acids or (ii) serine and glycine amino acids.

38 . The method of claim 37 , wherein the at least one linker comprises serine and glycine amino acids, and wherein at least 50% of the amino acids are glycine amino acids.

39 . The method of claim 27 , wherein the polyepitopic polypeptide further comprises epitopes not containing cancer specific somatic mutations which are expressed by cancer cells.

40 . The method of claim 20 , wherein the set comprises at least three pre-manufactured vaccine products each targeting a different shared tumor antigen.

41 . The method of claim 20 , wherein the shared tumor antigens in the set are each shared by at least 80% of subjects having the same cancer type.

42 . The method of claim 20 , wherein the first vaccine comprises at least one of the pre-manufactured vaccine products that comprises one or more RNA molecules encoding one or more T cell epitopes of one or more distinct shared tumor antigens expressed by the cancer cells of the cancer subject.

43 . The method of claim 20 , wherein the first immune response comprises a CD8+ immune response against one or more shared tumor antigens.

44 . The method of claim 20 , wherein the second immune response comprises a CD4+ immune response against one or more tumor antigens comprising the cancer-specific somatic mutations.

45 . The method of claim 20 , wherein the cancer is an adenocarcinoma.

46 . The method of claim 20 , wherein the cancer is a melanoma.

47 . The method of claim 20 , wherein the cancer subject is a human cancer subj ect.

48 . A method comprising:
(a) administering to a subject having a tumor of a particular cancer type a first vaccine comprising a set of pre-manufactured vaccine products, wherein each pre-manufactured vaccine product comprises one or more nucleic acids encoding one or more distinct shared tumor antigens, wherein the shared tumor antigens are each shared by at least 80% of subjects having the cancer type; and (b) administering to the subject a second vaccine comprising one or more nucleic acids encoding a plurality of neo-epitopes, wherein each neo-epitope comprises at least one cancer-specific somatic mutation that is determined to be present in a sample comprising cancer cells from the subject and not present in a sample comprising non-cancer cells from the same subject.

49 . The method of claim 48 , wherein the second cancer vaccine is produced by a process comprising steps of:
(i) providing a tumor specimen from the subj ect and a non-tumor specimen from the same subject; (ii) identifying sequence differences between the genome, exome and/or transcriptome of the tumor specimen and the genome, exome and/or transcriptome of the non-tumor specimen; (iii) designing peptides or a polypeptide comprising epitopes incorporating the sequence differences identified in step (ii); and (iv) producing a vaccine comprising one or more nucleic acids encoding the peptides or polypeptide designed in step (iii).

50 . The method of claim 48 , wherein the cancer-specific somatic mutations are present in the exome of cancer cells of the subject and are non-synonymous mutations.

Assignees

• BioNTech SE
• Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gg

Inventors

• Sahin Ugur
• Paret Claudia
• Vormbrock Kirsten
• Bender Christian
• Diekmann Jan

Classifications

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title

• A61K2039/627

  characterised by the linker · CPC title

• A61K2039/572

  cytotoxic response · CPC title

• A61K2039/605

  MHC molecules or ligands thereof · CPC title

• A61K39/0011 Primary

  Cancer antigens · CPC title